LOS ANGELES–(BUSINESS WIRE)–#bestinklass—Zynx Health, a pioneer and market leader in evidence- and experience-based clinical solutions, has been ranked #1 in KLAS Research’s 2022 Best in KLAS Awards in the category of Clinical Decision Support – Care Plans and Order Sets. Zynx Health received near-perfect scores across the grading criteria (Culture, Loyalty, Operations, Product, Relationship, Value) used to assess Best in KLAS status. The award marks Zynx Health’s sixth Best in KLAS designation.
“As COVID-19 continues to overwhelm hospitals, the availability of regularly updated evidence-based clinical decision support is more essential to frontline healthcare providers than ever before,” said Chuck Tuchinda, MD, president of Zynx Health. “Our Zynx Health physicians, nurses, pharmacists, and informaticists continue to work diligently to ensure our clients have access to actionable content shown to maximize performance. We are honored that our endeavors have again been recognized by the experts at KLAS Research.”
“Each year, thousands of healthcare professionals across the globe take the time to share their voice with KLAS. They know that sharing their perspective helps vendors to improve and helps their peers make better decisions. These conversations are a constant reminder to me of how necessary accurate, honest, and impartial reporting is in the healthcare industry,” said Adam Gale, KLAS CEO. “The Best in KLAS report and the awards it contains set the standard of excellence for software and services firms. Vendors who win the title of ‘Best in KLAS’ should celebrate and remember that providers now accept only the best from their products and services. The Best in KLAS award serves as a signal to provider and payer organizations that they should expect excellence from the winning vendors.”
About Zynx Health
Zynx Health, a market leader in providing evidence- and experience-based clinical improvement solutions since 1996 and part of the Hearst Health network, provides healthcare professionals with vital information and processes that guide care decisions and reduce complexity across the entire patient journey in a way that leads to healthier lives for all. Named the “Best in KLAS” Category Leader for Clinical Decision Support – Care Plans and Order Sets in 2021 and 2022, Zynx is a pioneer and market leader in evidence- and experience-based clinical solutions that help health systems improve patient outcomes, financial outcomes, clinical engagement, and technology performance. With Zynx Health, healthcare organizations exceed industry demands for delivering high-quality care at lower costs under value-based reimbursement models. To learn more, visit zynxhealth.com or call 888.996.9435. Follow Zynx Health on LinkedIn @Zynx-Health.
About Hearst Health
The mission of Hearst Health is to help guide the most important care moments by delivering vital information into the hands of everyone who touches a person’s health journey. Each year in the U.S., care guidance from Hearst Health reaches 85% of discharged patients, 205 million insured individuals, 103 million home health visits, and 3.2 billion dispensed prescriptions. The Hearst Health network includes FDB (First Databank), Zynx Health, MCG, Homecare Homebase, and MHK (formerly MedHOK). Hearst also holds a minority interest in the precision medicine and oncology analytics company M2Gen. Follow Hearst Health on Twitter @HearstHealth and LinkedIn @Hearst-Health.
About KLAS Research
KLAS has been providing accurate, honest, and impartial insights for the healthcare IT (HIT) industry since 1996. The KLAS mission is to improve the world’s healthcare by amplifying the voice of providers and payers. The scope of our research is constantly expanding to best fit market needs as technology becomes increasingly sophisticated. KLAS finds the hard-to-get HIT data by building strong relationships with our payer and provider friends in the industry. To learn more about KLAS, visit KLASresearch.com.
Contacts
David Yurkovich, MBA
Manager of Marketing
310.954.1968
Toronto, Ontario--(Newsfile Corp. - July 4, 2024) - FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE)…
MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) -- Global biotechnology leader CSL Behring (ASX: CSL)…
SKYSCRAPER-06 evaluating tiragolumab plus Tecentriq and chemotherapy did not meet the primary endpoints of progression-free…
ICPO Center NuMeRI ICPO Foundation signed the contract with Nuclear Medicine Research Infrastructure (NuMeRI) to…
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (the “Company”) (Nasdaq: PBM)…
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED…